
1. Lancet Psychiatry. 2021 Dec;8(12):1030-1031. doi: 10.1016/S2215-0366(21)00428-4.

Antipsychotics and COVID-19: the debate goes on - Authors' reply.

De Picker L(1), Mazza MG(2), Vai B(3).

Author information: 
(1)University Psychiatric Hospital Campus Duffel, 2570 Duffel, Belgium;
Collaborative Antwerp Psychiatric Research Institute, University of Antwerp,
Antwerp, Belgium. Electronic address: livia.depicker@uantwerp.be.
(2)Psychiatry & Clinical Psychology, Division of Neuroscience, IRCCS San Raffaele
Scientific Institute, Milan, Italy; University Vita-Salute San Raffaele, Milan,
Italy.
(3)Psychiatry & Clinical Psychology, Division of Neuroscience, IRCCS San Raffaele
Scientific Institute, Milan, Italy; Fondazione Centro San Raffaele, Milan, Italy.

Comment on
    Lancet Psychiatry. 2021 Sep;8(9):797-812.
    Lancet Psychiatry. 2021 Dec;8(12):1030.

DOI: 10.1016/S2215-0366(21)00428-4 
PMCID: PMC8601685
PMID: 34801117  [Indexed for MEDLINE]

Conflict of interest statement: LDP reports grants from Boehringer-Ingelheim and 
Janssen, outside the submitted work. LDP and BV are members of the ECNP
ImmunoPsychiatry Network. MGM declares no competing interests.

